Education
About Us
Working with TipRanks
Follow Us
Knight Therapeutics (TSE:GUD)
TSX:GUD
GUD Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$5.09 - C$6.45
Previous CloseN/A
Volume40.10K
Average Volume (3M)100.74K
Market Cap
$568.85M
Enterprise ValueC$441.39M
Total Cash (Recent Filing)C$244.78M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)131.1
Beta0.25
Next Earnings
May 08, 2025EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding99,448,490
10 Day Avg. Volume54,326
30 Day Avg. Volume100,738
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.79
Price to Cash Flow (P/CF)31.20
P/FCF Ratio48.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.91Price Target Upside37.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Knight Therapeutics News
PremiumCompany Announcements
Knight Therapeutics’ Earnings Call: Record Revenues Amid Challenges
PremiumCompany Announcements
Knight Therapeutics Reports Record-High Revenues in 2024
PremiumCompany Announcements
Knight Therapeutics Achieves Record Revenues and Expands Product Approvals---
Bulls Say, Bears Say
Bulls Say
Acquisition DealKnight announced that it will acquire the Paladin business unit from Endo Inc., including $20M of inventory.
Contract RenewalRevenues are expected to be higher due to Knight re-signing a $22.4M contract with the Brazilian Ministry of Health.
Revenue GrowthRevenues grew 31% year-over-year on an IFRS basis.
Bears Say
EBITDA MarginEBITDA margin was lower despite the revenue growth.
---
Options Prices
Currently, No data available
---
Ownership Overview
30.44% Insiders
2.22%
Mutual Funds
0.09% Other Institutional Investors
66.69% Public Companies and
Individual Investors
GUD FAQ
What was Knight Therapeutics’s price range in the past 12 months?
Knight Therapeutics lowest stock price was C$5.08 and its highest was C$6.45 in the past 12 months.
What is Knight Therapeutics’s market cap?
Knight Therapeutics’s market cap is $568.85M.
When is Knight Therapeutics’s upcoming earnings report date?
Knight Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 13 days.
How were Knight Therapeutics’s earnings last quarter?
Knight Therapeutics released its earnings results on Mar 20, 2025. The company reported C$0.11 earnings per share for the quarter, beating the consensus estimate of C$0.018 by C$0.092.
Is Knight Therapeutics overvalued?
According to Wall Street analysts Knight Therapeutics’s price is currently Undervalued.
Does Knight Therapeutics pay dividends?
Knight Therapeutics does not currently pay dividends.
What is Knight Therapeutics’s EPS estimate?
Knight Therapeutics’s EPS estimate is <0.01.
How many shares outstanding does Knight Therapeutics have?
Knight Therapeutics has 99,448,490 shares outstanding.
What happened to Knight Therapeutics’s price movement after its last earnings report?
Knight Therapeutics reported an EPS of C$0.11 in its last earnings report, beating expectations of C$0.018. Following the earnings report the stock price went up 0.32%.
Which hedge fund is a major shareholder of Knight Therapeutics?
Currently, no hedge funds are holding shares in TSE:GUD
---
Company Description
Knight Therapeutics
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.
---
GUD Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Knight Therapeutics reported record revenues and significant pipeline expansion but faced challenges with declining gross margins, decreased adjusted EBITDA, and competition from generic products. The acquisition of Paladin and new contracts in Brazil are positive, but these are offset by currency and hyperinflation challenges.Read More>---
GUD Stock 12 Month Forecast
Average Price Target
C$7.91
▲(37.02% Upside)
Technical Analysis
Microbix Biosystms
―
Biome Grow Inc
―
Neo Performance Materials Inc
―
HLS Therapeutics Inc
―
Best Analysts Covering GUD
1 Year
1 Year Success Rate
8/20 ratings generated profit
1 Year Average Return
-2.61%
reiterated a buy rating last month
Copying Douglas Miehm's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -2.61% per trade.
---